Literature DB >> 18759810

The level of illicit drug use is related to symptoms and premorbid functioning in severe mental illness.

P A Ringen1, I Melle, A B Birkenaes, J A Engh, A Faerden, A Vaskinn, S Friis, S Opjordsmoen, O A Andreassen.   

Abstract

OBJECTIVE: There is conflicting data on drug abuse and outcome in severe mental illness. This study aims to investigate if the amount of illicit psychoactive drug use is related to symptom load or premorbid functioning across diagnosis in patients with severe mental illness.
METHOD: Symptom load, sociodemographic status, premorbid functioning and the level of use of illicit psychoactive drugs were assessed in 423 subjects with schizophrenia or bipolar disorder in a cross-sectional study.
RESULTS: High amount of illicit drug use was associated with poorer premorbid academic functioning. In schizophrenia, there was a significant positive association between amount of drug use and severity of psychiatric symptoms. The association between symptom load and drug use was significant after controlling for premorbid functioning.
CONCLUSION: The results suggest a direct association between the quantity of current drug use and more severe symptoms in schizophrenia. Poor premorbid functioning was related to high amount of use, but did not explain the difference in symptom load.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18759810     DOI: 10.1111/j.1600-0447.2008.01244.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  19 in total

Review 1.  Prevalence and impact of substance use among emerging adults with serious mental health conditions.

Authors:  Ashli J Sheidow; Michael McCart; Kristyn Zajac; Maryann Davis
Journal:  Psychiatr Rehabil J       Date:  2012

2.  Pre-illness cannabis use and the early course of nonaffective psychotic disorders: associations with premorbid functioning, the prodrome, and mode of onset of psychosis.

Authors:  Michael T Compton; Beth Broussard; Claire E Ramsay; Tarianna Stewart
Journal:  Schizophr Res       Date:  2010-10-30       Impact factor: 4.939

3.  Heavy cannabis use prior psychosis in schizophrenia: clinical, cognitive and neurological evidences for a new endophenotype?

Authors:  Jasmina Mallet; Nicolas Ramoz; Yann Le Strat; Philip Gorwood; Caroline Dubertret
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-02-11       Impact factor: 5.270

4.  Comorbid mental disorders in substance users from a single catchment area--a clinical study.

Authors:  Anne-Marit Langås; Ulrik F Malt; Stein Opjordsmoen
Journal:  BMC Psychiatry       Date:  2011-02-12       Impact factor: 3.630

5.  The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample.

Authors:  Murat Yücel; Emre Bora; Dan I Lubman; Nadia Solowij; Warrick J Brewer; Sue M Cotton; Philippe Conus; Michael J Takagi; Alex Fornito; Stephen J Wood; Patrick D McGorry; Christos Pantelis
Journal:  Schizophr Bull       Date:  2010-07-25       Impact factor: 9.306

Review 6.  Work, recovery, and comorbidity in schizophrenia: a randomized controlled trial of cognitive remediation.

Authors:  Susan R McGurk; Kim T Mueser; Thomas J DeRosa; Rosemarie Wolfe
Journal:  Schizophr Bull       Date:  2009-03-05       Impact factor: 9.306

7.  Previous hospital admissions and disease severity predict the use of antipsychotic combination treatment in patients with schizophrenia.

Authors:  Albert Bolstad; Ole A Andreassen; Jan I Røssberg; Ingrid Agartz; Ingrid Melle; Lars Tanum
Journal:  BMC Psychiatry       Date:  2011-08-03       Impact factor: 3.630

8.  Cannabis use and cognition in schizophrenia.

Authors:  Else-Marie Løberg; Kenneth Hugdahl
Journal:  Front Hum Neurosci       Date:  2009-11-24       Impact factor: 3.169

Review 9.  Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable?

Authors:  Jørgen G Bramness; Øystein Hoel Gundersen; Joar Guterstam; Eline Borger Rognli; Maija Konstenius; Else-Marie Løberg; Sigrid Medhus; Lars Tanum; Johan Franck
Journal:  BMC Psychiatry       Date:  2012-12-05       Impact factor: 3.630

Review 10.  Pathways from cannabis to psychosis: a review of the evidence.

Authors:  Jonathan K Burns
Journal:  Front Psychiatry       Date:  2013-10-14       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.